	Application No.	Applicant(s)
	10/690,118	ALBANIEZE WALKED ET AL
Notice of Allowability	Examiner	ALBANEZE-WALKER ET AL. Art Unit
	Bernard Dentz	1625
	Demaid Demz	1625
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>Amdt. of 7-1-2004</u> .		
2. The allowed claim(s) is/are 14,2-6,10 and 15-20 renumbered respectively 1-13.		
3. The drawings filed on are accepted by the Examiner.		
4. ☐ Acknowledgment is made of a claim for foreign priority una) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. ☐ A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give	e been received. e been received in Application Not cuments have been received in t of this communication to file a re IENT of this application. et the attached EXAMIN the reason(s) why the oath or dec	b  his national stage application from the ply complying with the requirements  JER'S AMENDMENT or NOTICE OF
6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) I including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
<ol> <li>□ hereto or 2) □ to Paper No./Mail Date</li> <li>□ including changes required by the attached Examiner's Amendment / Comment or in the Office action of</li> </ol>		
Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summ Paper No./Mail 8), 7. ☒ Examiner's Ame	Date

Application/Control Number: 10/690,118

Art Unit: 1625

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows: After the title at p. 1 - - This application derives priority from verified Provisional Applications 60/428315 filed May 22, 2003 and 60/472598 filed Nov. 22, 2002. - - has been inserted.

The following is an examiner's statement of reasons for allowance: See applicants' arguments relating to the fact that in the examples of the reference that the boron containing intermediate is a naphthyridinone amide while applicants' boron containing intermediate is a naphthyridinone ester. Also note that in the Scheme 1 of the reference that when the naphthyridinone ester is used as the intermediate that the boron containing group is not on it but on the other reactant. Further note the difference in the conversion of the naphthyridinone ester X to the naphthyridinone amide I. In the reference after hydrolysis to the carboxylic acid, the acid is converted to the acid halide or anhydride while in the instant case it is converted directly to the amide.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 10/690,118

Art Unit: 1625

Page 3

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8 to 4:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

B. Dentz

7-20-2004

Bernard Uentz Primary Examiner Group 1200